Clinical Trial Update: Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias [Phase 2]

View source ↗

Summary

Phase 2 study of deferasirox for iron overload in beta-thalassemia patients who cannot be treated with deferoxamine, as well as related chronic anemias; the tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia
• Beta-thalassemia
• Diamond-blackfan Anemia
• Fanconi Anemia
• Myelodysplastic Syndromes

Drugs mentioned

• Deferasirox (Deferasirox)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Beta-thalassemia, Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED